Journal
AMERICAN JOURNAL OF OPHTHALMOLOGY
Volume 147, Issue 4, Pages 667-678Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajo.2008.11.009
Keywords
-
Categories
Ask authors/readers for more resources
PURPOSE: To describe clinical features of chronic anterior uveitis in children at presentation to a referral center (baseline); to identify relationships between demographic, medical, and ophthalmic factors at baseline; and to determine baseline factors that predict new complications and vision loss during follow,up. DESIGN: Retrospective case series. METHODS: Studied were involved eyes of all children (age <= 16 years at disease onset) with chronic anterior uveitis who were examined by I clinician from 1993 through 2006. Cross,sectional analyses compared based line findings. Relationships between potential risk factors and incident adverse events (new complications, vision loss) were studied by Kaplan-Meier and Cox proportional hazards regression models. RESULTS: There were 115 patients (200 eyes) who met inclusion criteria. Follow,up (n = 83 patients) ranged from 0.4 to 157.5 months (median, 23.5 months). There were numerous strong relationships between 8 defined complications at baseline in pairwise comparisons. Flare was the inflammatory sign most consistently associated with complications at baseline. Baseline factors that predicted new complications during follow-up included age <= 3 years, elevated cells, elevated flare, keratic precipitates, signs of intermediate uveitis, and papillitis (all P < .043); factors that predicted vision loss included male gender, increased flare, signs of intermediate uveitis, papillitis, and baseline complications (all P < .015). Not related to new complications were presence of juvenile idiopathic uveitis and immunomodulatory therapy. CONCLUSION: Chronic anterior uveitis in children is associated with various vision-threatening complications that occur in combinations. Complications develop early in the disease course. Patients with more severe disease at presentation are at increased risk of additional adverse events. (Am J Ophthalmol 2009; 147: 667-678. (C)2009 by Elsevier Inc. All rights reserved.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available